CASI Pharmaceuticals Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
CASI Pharma (CASI) Misses Q1 EPS by 5c, Revenues Beat
May 13, 2021 7:10 AM EDTCASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.11), $0.05 worse than the analyst estimate of ($0.06). Revenue for the quarter came in at $5.74 million versus the consensus estimate of $5.05 million.
Wei-Wu He, Ph.D., CASI's Chairman, and Chief Executive Officer, commented, "We are pleased to report $5.7 million EVOMELA® revenues for the quarter. For the full year 2021, we... More
